Genentech Faces Arbitration Over Cancer Drug Licensing
PDL BioPharma Inc. said Tuesday that it had hit Genentech Inc. with an arbitration action in New Jersey for allegedly underpaying pharmaceutical royalties on license agreements related to cancer drugs and...To view the full article, register now.
Already a subscriber? Click here to view full article